EUVIMEDEUVIMED entdecken
Crossref

The role of fingolimod in managing anxiety and depression in patients with multiple sclerosis

Maryam Poursadeghfard, Donya Shadfar, Mahsa Kalaee, Etrat Hooshmandi, Mahnaz Bayat

Journal of Affective Disorders · 2026

DOI: 10.1016/j.jad.2025.120986 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026. Verfasst von Maryam Poursadeghfard und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Neurology, Shiraz University of Medical Scienc…. Hauptthemen laut MEDLINE: Fingolimod Hydrochloride, Multiple Sclerosis, Relapsing-Remitting, Immunosuppressive Agents, Anxiety. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Vice-Chancellor for Research, Shiraz University of Medical Sciences, Shiraz University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anxiety and depression are common comorbidities among patients with multiple sclerosis (MS). Fingolimod, an oral disease-modifying therapy, may offer psychological benefits in addition to its immunomodulatory effects. This study aimed to evaluate the impact of fingolimod on anxiety and depression levels and to identify associated risk factors in patients with relapsing-remitting MS (RRMS). METHODS: A prospective cohort study was conducted on 61 RRMS patients who initiated fingolimod treatment for the first time at Imam Reza Clinic, Shiraz, Iran. Psychological symptoms were assessed using the Hospital Anxiety and Depression Scale at baseline and treatment. Paired t-tests were used to evaluate score changes. Logistic regression analyses identified predictors of baseline depression. ANCOVA was performed to assess post-treatment anxiety and depression while controlling for baseline scores. RESULTS: After four months, mean anxiety (5.2 ± 4.2 to 4.9 ± 4.0; p = 0.50) and depression scores (5.0 ± 3.8 to 4.5 ± 3.4; p = 0.30) showed no significant changes. At baseline, MS relapses (OR = 4.7, p = 0.02) and prior medication (OR = 5.9, p = 0.03) use were associated with depression, and recent sad life events with anxiety. After controlling for baseline scores using ANCOVA, no factors were significantly associated with post-treatment anxiety or depression. CONCLUSION: In this study, four months of fingolimod treatment was not associated with significant changes in anxiety or depression in patients with RRMS. Baseline predictors, including relapses, prior medication use, and recent sad events, were no longer significant after treatment, suggesting a potential treatment-related modulation of psychological effects. Future research in patients with higher disability and more severe symptoms is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fingolimod HydrochlorideMultiple Sclerosis, Relapsing-RemittingImmunosuppressive AgentsAnxietyDepressionHumansFemaleMaleAdultProspective StudiesMiddle AgedIranTreatment Outcome

Stichwörter der Autor:innen

AnxietyDepressionFingolimodHospital Anxiety and Depression Scale (HADS)Multiple sclerosis

Substanzen

Fingolimod HydrochlorideImmunosuppressive Agents

Autor:innen und Institutionen

  • Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: ma_bayat@sums.ac.ir.

Förderung

  • Vice-Chancellor for Research, Shiraz University of Medical Sciences
  • Shiraz University of Medical Sciences

Zitieren

APA

Poursadeghfard, M., Shadfar, D., Kalaee, M., Hooshmandi, E., & Bayat, M. (2026). The role of fingolimod in managing anxiety and depression in patients with multiple sclerosis. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.120986

Vancouver

Poursadeghfard M, Shadfar D, Kalaee M, Hooshmandi E, Bayat M. The role of fingolimod in managing anxiety and depression in patients with multiple sclerosis. Journal of Affective Disorders. 2026. doi:10.1016/j.jad.2025.120986

BibTeX
@article{Poursadeghfard2026,
  author = {Poursadeghfard, Maryam and Shadfar, Donya and Kalaee, Mahsa and Hooshmandi, Etrat and Bayat, Mahnaz},
  title = {The role of fingolimod in managing anxiety and depression in patients with multiple sclerosis},
  journal = {Journal of Affective Disorders},
  year = {2026},
  doi = {10.1016/j.jad.2025.120986}
}
Kostenlos starten →